GW Pharmaceuticals CBD drug gets regulatory OK in Australia

GW Pharmaceuticals’ plant-derived CBD drug Epidyolex received approval from Australia’s Therapeutic Goods Administration (TGA) to be used in treating seizures related to Lennox-Gastaut syndrome and Dravet syndrome for patients 2 and older.

GW Pharmaceuticals CBD drug gets regulatory OK in Australia is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs